We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

60 hedge funds and large institutions have $60.8M invested in Theriva Biologics in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 9

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

2% less funds holding

Funds holding: 61 → 60 (-1)

5% less capital invested

Capital invested by funds: $64.2M → $60.8M (-$3.39M)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
60
Holders Change
-1
Holders Change %
-1.64%
% of All Funds
1.6%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
6
Increased
17
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$150K
2
State Street
State Street
Massachusetts
+$120K
3
New York State Common Retirement Fund
New York State Common Retirement Fund
New York
+$59.9K
4
Wells Fargo
Wells Fargo
California
+$59.9K
5
Fisher Asset Management
Fisher Asset Management
Washington
+$44.9K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$224K
2
William Blair & Company
William Blair & Company
Illinois
-$180K
3
Millennium Management
Millennium Management
New York
-$92K
4
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$74.8K
5
M&T Bank
M&T Bank
New York
-$66K
Name Holding Trade Value Shares
Change 		Change in
Stake
Principal Financial Group
51
Principal Financial Group
Iowa
$23K – – –
Deutsche Bank
52
Deutsche Bank
Germany
$21K – – –
SFSIG
53
San Francisco Sentry Investment Group
California
$21K +$15K +1 New
SG Americas Securities
54
SG Americas Securities
New York
$19K +$15K +1 New
JCM
55
Jacobi Capital Management
Pennsylvania
$17K – – –
SO
56
STRS Ohio
Ohio
$14K -$29.9K -2 -67%
Citigroup
57
Citigroup
New York
$12K – – –
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$8.85K +$15K +1 New
TWA
59
TCI Wealth Advisors
Arizona
$7K – – –
BlackRock
60
BlackRock
New York
$5K – – –
AA
61
Apriem Advisors
California
$3K – – –
KF
62
Krilogy Financial
Missouri
$2K – – –
MFS
63
MSI Financial Services
Massachusetts
$2K – – –
Barclays
64
Barclays
United Kingdom
$1K – – –
TCIM
65
TIAA CREF Investment Management
New York
$430 -$29.9K -2 -6%
VOYA Investment Management
66
VOYA Investment Management
Georgia
$66 – – –
Millennium Management
67
Millennium Management
New York
– -$92K -6 Closed
M&T Bank
68
M&T Bank
New York
– -$66K -4 Closed
Jacobs Levy Equity Management
69
Jacobs Levy Equity Management
New Jersey
– -$44K -3 Closed
MWM
70
Mission Wealth Management
California
– -$42K -3 Closed
BCM
71
Bayesian Capital Management
New York
– -$31K -2 Closed
Citadel Advisors
72
Citadel Advisors
Florida
– -$39K -2 Closed
AllianceBernstein
73
AllianceBernstein
Tennessee
– -$21K -1 Closed
AIM
74
Acrospire Investment Management
Illinois
– -$3K – –
PCM
75
Prelude Capital Management
New York
– -$1K – –
1 2
3

TOVX Hedge Fund Activity: Q3 2016 in Review

60 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2016, worth a combined $60.8M — down 5.3% from $64.2M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TOVX and 6 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 17 added.

The largest buyer was BlackRock Fund Advisors, adding an estimated $150K. The largest seller was Bridgeway Capital Management, cutting an estimated $224K.

  • 60 institutional investors held Theriva Biologics (TOVX) as of Q3 2016, down from 61 in Q2 2016.
  • Funds reported $60.8M of Theriva Biologics stock for Q3 2016, down 5.3% quarter-over-quarter.
  • 6 funds opened new Theriva Biologics positions in Q3 2016 and 7 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $150K added.
  • The largest Theriva Biologics seller in Q3 2016 was Bridgeway Capital Management, an estimated $224K sold.

Based on aggregated 13F filings for Q3 2016.